An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The management team will also host virtual investor meetings during the event. A pre-recorded presentation will be available from 7:00 AM ET on January 10 and can be accessed on the Company's investors section of its website, with a replay available for 90 days. Ocular Therapeutix focuses on innovative therapies for eye conditions.
Positive
None.
Negative
None.
BEDFORD, Mass.--(BUSINESS WIRE)--
Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.
In addition to the presentation, the management team will host virtual investor meetings. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their H.C. Wainwright representative.
A webcast of the pre-recorded presentation will be made available the morning of the conference starting at 7:00 AM ET on Monday, January 10th, and can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. It will be available for replay for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix has completed Phase 2 clinical trials for OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix's first product, ReSure® Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
Media
Ocular Therapeutix Scott Corning Senior Vice President, Commercial
scorning@ocutx.com
Source: Ocular Therapeutix, Inc.
FAQ
When will Ocular Therapeutix present at the BioConnect 2022 Virtual Conference?
Ocular Therapeutix will present at the BioConnect 2022 Virtual Conference from January 10-13, 2022.
What time will Ocular Therapeutix's presentation be available?
The pre-recorded presentation will be available starting at 7:00 AM ET on January 10, 2022.
How can investors access Ocular Therapeutix's presentation?
Investors can access the presentation on the investors section of Ocular Therapeutix's website at investors.ocutx.com.
Will there be a replay of Ocular Therapeutix's presentation?
Yes, the presentation will be available for replay for 90 days after the conference.
What is the focus of Ocular Therapeutix as a biopharmaceutical company?
Ocular Therapeutix focuses on innovative therapies for diseases and conditions of the eye using proprietary bioresorbable hydrogel-based formulation technology.
